{
  "docId": "019de076-86c0-778c-b811-8ed1a345f3e4",
  "docSlug": "3a23784462a131093cb118313f70597a",
  "documentTitle": "NeuroBo Pharmaceuticals | Investor Presentation Deck | 25 slides",
  "authorId": "neurobo-pharmaceuticals",
  "authorName": "NeuroBo Pharmaceuticals",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 25,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "unfair_advantage",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a hub-and-spoke diagram to illustrate the multi-faceted mechanism of action of the drug target.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-86c0-778c-b811-8ed1a345f3e4/14",
  "deckHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4",
  "deckJsonHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4.json",
  "deckAnchorHref": "/decks/019de076-86c0-778c-b811-8ed1a345f3e4#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.4,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Mechanism of action diagram showing GPR119 at the center with three main branches of biological effects.",
      "attrs": null,
      "subkind": "hub-spoke",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd4d51f6-334b-4ac7-8ba0-6ca5a8282a28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "list",
      "text": "GPR119 therapeutic target is to inhibit steatosis, inflammation and fibrosis and the treatment or progression of MASH. DA-1241 is an advanced GPR119 agonist with proven enhanced efficacy in animal models. Its effect is enhanced when combined with a DPP4 inhibitor",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2e5d66ab-a47e-443b-aa4d-d4e967281831",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.6,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "DA-1241: Potential Advantages in MASH",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e206c1fc-8a84-45a1-b235-5d751f1c26cb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "4474e02c-3b96-490a-ac0c-b16762a41f48",
      "evidence": "diagram/hub-spoke: Mechanism of action diagram showing GPR119 at the center with three main branches of biological effects.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "hub-spoke",
      "slug": null,
      "matchId": "4601dc9a-a8b8-46b6-8492-77c09d6c3a49",
      "evidence": "Central GPR119 node branching into three distinct functional categories of biological effects.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 20,
      "from": 13,
      "beatId": "0b194b23-dcf9-4757-99ec-a26b7f11f2c1",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "Slides 13-20 provide information on DA-1241 and DA-1726, including clinical trials and comparisons",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}